Advertisement
U.S. recommendations against the prostate-specific antigen test for prostate cancer might have prompted a small but measurable increase in the number of higher-risk cases diagnosed recently

ASCO: High-Risk Prostate Cancer Diagnosis Up Since New PSA Recs

0
Researchers report 3 percent annual rise in intermediate- and high-risk cases
Patients with metastatic colorectal cancer that started on the left side may be more likely to survive than those whose disease originated on the right side

Location of Colorectal Cancer Factors Into Survival

0
Poorer outcome seen in study when tumor began on the organ's right side
Suicide is a public health concern for patients with genitourinary cancer

Suicide Deemed Public Health Concern in Genitourinary Cancers

0
Risk factors include male gender, distant disease, increasing age, race/ethnicity
For aspirin-sensitive patients undergoing everolimus-eluting stent implantation

Six-Month Dual Antiplatelet Tx Noninferior to 24-Month DAPT

0
Findings show noninferiority for six-months of treatment in aspirin-sensitive patients
Patients with allergic rhinitis may have an increased risk of developing nasopharyngeal carcinoma

Nasal Allergies Tied to Increased Nasopharyngeal Cancer Risk

0
Even higher risk seen for patients with repeated visits for allergic rhinitis
Men who've had testicular cancer may be at increased risk for prostate cancer

ASCO: Testicular Cancer May Raise Risk of Prostate Cancer

0
But it's too soon to make any recommendations, and overall risk is low, researcher says
Choosing active surveillance over treatment for prostate cancer may decrease the odds of survival in men with intermediate-risk cancer

ASCO: Survival Down in Some Cases of Active Surveillance

0
Lower survival for intermediate-risk disease, compared to low-risk cases
A single-nucleotide polymorphism in the promoter region of the CEP72 gene

SNP Linked to Vincristine-Related Neuropathy in ALL

0
SNP in promoter region of CEP72 gene linked to risk and severity of neuropathy in children with ALL
Farydak (panobinostat) has been approved by the U.S. Food and Drug Administration to treat multiple myeloma. Farydak inhibits the activity of histone deacetylases

FDA Approves Farydak for Multiple Myeloma

0
Drug is sanctioned for people who have received at least two prior standard therapies
The use of power morcellation to remove fibroids in the uterus can end up spreading bits of hidden cancerous tumors throughout the abdomen

Cancer Prevalence Low in Power Morcellation Fibroid Removal

0
Researchers call the findings 'reassuring,' but FDA warnings remain for older women